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Abstract .  Photodynamic therapy (PDT) with topical application of 5-aminolaevulinic a id (ALA, 
20% w/w) was used to treat superficial basal cell carcinoma (BCC, 16 patients), Morbus Bowen (one 
patient), basal cell naevus syndrome (BCNS, three patients), actinic keratosis (AK, two patients), 
chronic inflammation (CI, one patient), and metastasized BCC (one patient). The interval between 
ALA application and il lumination was 3-6 h. The incident light dose was 50-100 J cm 2, mostly 
75 J cm -2, at 633 nm wavelength. This was based on the fluorescence xcitation spectrum, 
measured on the skin of human volunteers. In a few cases, 514.5 nm light was used. A complete 
response (CR) rate of 79% (median follow-up 13 months) was obtained with 42 BCC lesions._The 
treatment of five areas with AK, two areas with CI and one area with M. Bowen yielded three CR 
for AK and five partial remissions (PR). Photodynamic therapy of metastasized BCC, after either 
topical or oral ALA, was not successful. Treatment of BCNS was satisfactory with 100% CR in one 
patient (22 lesions), PR in a second patient (20 lesions), and good palliation in a third patient (>250 
lesions). The treatment was well tolerated, although the il lumination had to be interrupted 
occasionally due to pain. Healing usually occurred in 2 weeks. Cosmetic results were good to 
excellent. 5-Aminolaevulinic acid application over 16-19 h and repeated treatments made it 
possible to obtain CR of non-superficial lesions. The selective tumour fluorescence was then lost, 
however, due to fluorescence of normal skin, but the cosmetic outcome did not deteriorate. 
5-Aminolaevulinic acid PDT may be a good alternative outpatient treatment, especially in elderly 
patients and for large treatment areas. The excellent cosmetic outcome warrants further study in 
younger patients. More work is necessary to establish optimal ALA-treatment schemes. 
INTRODUCTION 
Primary skin cancer is the most common 
malignancy in man, which can usually be 
treated successfully by several modalities, 
such as surgical excision, cryotherapy or 
radiotherapy (1). All modalities have their 
specific advantages and disadvantages, till 
leaving room for improvement. Furthermore, 
when treatment modalities achieve a near- 
maximal result (cure), side issues become more 
important, such as overall treatment ime, 
complications and cosmetic results. 
Photodynamic therapy (PDT) is a new 
cancer treatment modality that is particularly 
suited to the treatment of superficial malignan- 
cies. The basis of PDT is the use of a non-toxic 
drug, a photosensitizer, which after accumula- 
tion in the target tissue is photo-activated in 
situ. The resultant photochemical reaction 
releases highly reactive singlet oxygen which 
is cytotoxic (2). This process is non-selective 
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in principle, and tumour specificity depends on 
a relatively high accumulation of the photo- 
sensitizer in tumour tissue after systemic 
administration, combined with well-directed 
illumination. The most widely studied photo- 
sensitizer is Photofrin, a drug that has been 
approved for a limited number of clinical indi- 
cations in Canada, The Netherlands, Japan 
and the USA. Photodynamic therapy using 
Photofrin and superficial il lumination has 
resulted in complete response (CR) rates of 
88% (3) and 96% (4) for basal cell carcinomas 
(BCC), and near 100% CR for Bowen's disease 
(5, 6). Although Photofrin is a potent photo- 
sensitizer, a major side-effect is prolonged cu- 
taneous photosensitivity compelling patients 
to avoid exposure to direct sunlight or bright 
daylight for 4-6 weeks after treatment (7, 8). 
Therefore, PDT with a standard dose of 
Photofrin (2 mg kg-1) is not an ideal treat- 
merit for primary skin cancer. Reduction of 
the Photofrin dose to i mg kg-1 (3) improves 
the therapeutic ratio, but does not solve the 
problem of skin photosensitivity completely. 
An alternative form of PDT, avoiding gener- 
alized skin phototoxicity, has been introduced 
by Kennedy et al (9), using endogenous 
photosensitization by topically applied 5- 
aminolaevulinic a id (ALA). 5-Aminolaevulinic 
acid is a precursor of protoporphyrin IX (PpIX) 
in the biosynthetic pathway for haem. Several 
steps in this pathway are rate-limited and 
tightly regulated. The feedback mechanisms 
can be bypassed by administering excess 
amounts of exogenous ALA, resulting in an 
accumulation i the cells of PpIX, an effective 
photosensitizer. Exposure to photo-activating 
light of appropriate wavelength and dose 
generates a characteristic red fluorescence 
and phototoxic ell damage (10, 11). This form 
of PDT will be called ALA-PDT. Kennedy 
reported a CR rate of 79% for superficial BCC 
after one il lumination (12), following topical 
application for 3-6 h of 20% ALA in an oil-in- 
water emulsion. 
The authors' interest in ALA-PDT started 
when a patient with basal cell naevus syn- 
drome (BCNS), having extensive BCC lesions, 
was presented for PDT. This patient had been 
treated with all conventional modalities which 
were ineffective. Photofrin-PDT would involve 
photosensitization f this patient for a long 
time, because of the many lesions requiring 
treatment. The response of this patient to 
topical ALA-PDT was so encouraging that a 
clinical study of ALA-PDT for superficial BCC 
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and actinic keratosis was started. The results 
of this study on 23 patients are reported in this 
paper. 
MATERIALS AND METHODS 
5-Aminolaevulinic acid and solvent 
The ALA was supplied by Janssen Pharma- 
ceuticals, Beerse, Belgium. Initially, a cream 
obtained from the hospital pharmacy 
('Lanette') was used as solvent. Instillagel | 
was later used which has a lower viscosity and 
contains 2% ]idocaine. 
Protoporphyrin IX fluorescence excitation 
spectrum 
At the start of this study, nothing was known 
about the action spectrum for PDT with endo- 
genously generated PpIX. Determining an in 
vivo action spectrum with an accuracy that 
yields a wavelength resolution better than 
5 nm involves a considerable amount of work, 
as was shown by the authors' study on the 
action spectrum for Photofrin-PDT (13). How- 
ever, for Photofrin-PDT it appeared that the in 
vivo absorption spectrum, the fluorescence 
excitation spectrum and the PDT-action spec- 
trum all had a maximum at 625 nm (14). There- 
fore, since a similar coincidence of maxima 
might occur for PpIX, the in vivo fluorescence 
excitation spectrum of PpIX was measured. 
This measurement can be made accurately and 
relatively easily. 5-Aminolaevulinic (20%) was 
applied to two areas of i cm 2 on the skin (arm) 
of three volunteers. The application time 
before measurement of one spot was 5-6 h, and 
of the other spot was 18 h. The fluorescence 
was excited with light from an argon pumped 
dye laser (620-650 nm, 1 nm linewidth) at inter- 
vals, between 620 and 650 nm, of 5 nm, and 
2.5 nm near the maximum using an irradiance 
of 0.1mW cm-2. The wavelengths were 
selected with a monochromator that was cali- 
brated against a He-Ne laser. Fluorescence 
was also excited with the argon laser at wave- 
lengths of 488, 496.5, 501.7 and 514.5 nm. The 
fluorescence was measured with a digital 
intensified CCD camera, through a 700 9 20 nm 
band pass filter. 
Photodynamic therapy 
Local Ethical Committee approval was  
obtained for this study, as was individual 
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informed consent. Pat ients  were recrui ted 
from the Depar tment  of Dermatology,  
Univers i ty  Hospita l  Rotterdam, Dijkzigt, The 
Nether lands,  and from the Departments  of 
Plast ic Surgery and Radiotherapy of the 
Daniel  den Hoed Cancer Centre, Rotterdam, 
The Nether lands.  Pat ients  with cl inical ly 
superficial lesions (_<3mm thickness) were 
considered eligible. Most lesions were very 
superficial (< lmm).  Biopsies were obtained 
from single lesions before t reatment.  In case of 
mult iple lesions, only two or three represen- 
tat ive lesions were biopsied. Pat ients  with 
histological ly confirmed BCC, Morbus Bowen 
or act inic keratosis  were included in this 
study. Twenty-three pat ients  were t reated with 
ALA-PDT, 10 males and 13 females, with a 
mean age of 65 yr (range 35 89 yr). 
Lesions were examined and measured care- 
fully, and crusts were removed. A 20% ALA 
solut ion (w/w) was appl ied to the lesion plus a 
marg in  of approx imate ly  5 -10mm of appar- 
ently normal  skin. The area was covered with a 
very thin gauze soaked in ALA solution, as a 
form of ALA reservoir ,  and was occluded with 
Tegaderm | The first 16 pat ients  were t reated 
after an ALA appl icat ion t ime of 3-6 h, which 
was extended to 16 19 h for some later pat ients  
and for retreatments .  The non-absorbed cream 
was wiped from the skin just before i l lumina- 
t ion with 633 nm l ight (see Results) from an 
argon pumped dye laser (Spectra Physics 
2040E and 375B, respectively).  In a few cases of 
very superficial lesions, 514.5 nm light from the 
argon laser was used. The l ight was focused 
into a 600 pm diameter  opt ical  fibre, guided to 
the t reatment  room and imaged through a lens 
system to produce a c i rcular  t reatment  field 
with a uni form l ight intensity. The irradiance, 
measured with a Spectra Physics SP407 power 
meter, was 50-100mW cm -2. Incident l ight 
doses of 50-100 J cm-2  were applied (mostly 
75 J  cm 2). The PpIX f luorescence was 
either measured ur ing t reatment  or v isual ly 
observed through a coloured glass filter 
(Schott RG665). At the end of the i l lumination, 
the f luorescence was always photobleached 
completely. T reatment  fields were typical ly 
3-8 cm in diameter, and the t reatment  imes 
were 10-30 min. 
After t reatment ,  pat ients  were seen in the 
outpat ient  clinic at regular  intervals for evalu- 
ation. Tumour  responses and cosmetic results 
were scored cl inical ly and by evaluat ion of 
colour photographs,  which were taken before 
t reatment  and dur ing the follow-up of every 
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Fig. 1. Fluorescence xcitation spectrum from 620 nm to 
650 nm of 5-aminolaevulinic-acid-induced protoporphyrin IX 
in normal human skin in vivo. Emission was measured in a 
band of 700_+20 nm. Mean of six spots, three subjects. The 
data from all spots were normalized to 100 at 630 nm. If no 
error bar is visible, it is smaller than a solid square. 
patient. A CR was defined as absence of clini- 
cal ly evident tumour  at the site of t reatment  
after 2 3 months.  Par t ia l  response was defined 
as at least 50% reduct ion in tumour  size. Pro- 
gressive disease (PD) is at least 25% tumour  
growth, and otherwise the response was classi- 
fled as stable disease (SD). The mean follow- 
up for all pat ients was 17 months (range 
1-54 months); for the BCC pat ients only, this 
was 13 months (range 1-39 months). 
The cosmetic outcome of the CR lesions was 
ciassified as excel lent (absence of any visible 
sign of lesion or st igmata of treatment),  good 
(slightly visible), fair  (moderate discoloration) 
or poor (strong hyperp igmentat ion)  in the 
t reatment  area. 
RESULTS 
Protoporphyrin fluorescence excitation 
spectrum 
The PpIX f luorescence xcitat ion spectrum in 
the red spectral  region in the hea l thy  volun- 
teers is shown in Fig. 1. The max imum is at 
633 + i nm. There was no measurable  differ- 
ence between the f luorescence xcitat ion spec- 
t ra after 5-6 h and 18 h ALA appl icat ion time. 
Therefore, these data were taken together  and 
the average was plotted in Fig. 1. The avail- 
able argon laser l ines could not define the 
local f luorescence excitat ion maximum. For 
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Photofr in,  this max imum is close to 500 nm 
(15). For PpIX, the f luorescence increased with 
increasing wavelength but showed a tendency 
to f latten at 514.5 nm (data not shown). For 
PpIX, the max imum may therefore be at or 
sl ightly above 514.5 nm. 
Photodynamic therapy 
The t reatment  was general ly well tolerated. 
However,  on several  occasions, the i l lumina- 
t ion had to be interrupted or the i r radiance 
reduced due to pain. The authors  now often 
start  the t reatment  with 50 mW cm 2 irradi- 
ance, which is gradual ly  increased to 100 mW 
cm 2 as the t reatment  progresses and the 
PpIX-f luorescence is photobleached. I t  ap- 
peared to the authors  that  after 16-19 h of ALA 
appl icat ion, more pat ients complained about  
pain and the pain was more intense. Emla |
ointment,  oral pain rel ievers (paracetamol,  
naproxen or tramadol)  or l idocaine inf i l trat ion 
were appl ied with vary ing success. After illu- 
minat ion,  the t reated area was usual ly reddish 
and sl ightly swollen, and sometimes some 
serous exudat ion was seen during and after 
i l luminat ion.  A crust usual ly developed, which 
fell of[ with in 14 days. Heal ing rare ly  took 
more than  3 weeks. Redness or p igmentat ion 
may take a few months to disappear,  usual ly 
wi thout  a visible scar. 
Basal cell naevus syndrome (BCNS) 
Mult ip le lesions in three pat ients  with BCNS 
were t reated in numerous sessions. In one 
patient,  all t reated lesions (22 in 10 l ight fields) 
showed a CR. This pat ient  was i l luminated 
with 100 J cm -2 of green l ight (514.5 rim) at 
150 mW cm-2 .  The pat ient  felt i tching rather  
than  pain. The response was strong; pigmenta- 
t ion remained for months but all lesions even- 
tual ly  healed scar-free. In the second patient,  
the most act ive lesions were treated, result ing 
in a CR or PR. A l though most lesions did not 
d isappear completely clinically, they remained 
quiescent for at least 15 months. The third 
pat ient  has a l ready been ment ioned in the 
introduct ion.  This pat ient  had so many lesions 
that  only a few of the most act ive ones could be 
t reated in one session. The best result  in this 
pat ient  was pal l iat ion using ALA-PDT and, 
occasional ly,  c ryotherapy or plastic surgery. 
Lesion th ickness ranged from very superficial 
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to th ick (several mm). All types of response 
occurred after one or more t reatments  by ALA- 
PDT. Numerous  lesions were retreated several  
t imes over more than  5 yr (total>250). In this 
patient,  CR of a few non-superf icial  lesions 
could be obta ined by three or more ALA-PDT 
t reatments  over several  weeks. Occasional ly,  
mil ia developed in areas that  were t reated 
repeatedly,  which may be regarded as an 
adverse cosmetic result. 
Basal cell carcinoma (BCC) 
Forty-two superficial BCCs were t reated in 16 
patients. The results are summarized in Table 
1. An init ial  CR rate of 81% (34 of 42 lesions) 
was seen with only one recurrence after 14 
months, so the recurrence-free CR rate is 79% 
(33 of 42 lesions). In 19% (eight of 42 lesions), 
only a PR was achieved (follow-up 1 39 
months, average 13 months). In one patient,  a 
lesion with a poorly-defined boundary  devel- 
oped a recurrence at the edge of the t reatment  
field. The cosmetic result  was usual ly good to 
excellent, and t iny scars developed only in 
skin a l ready damaged by the tumour.  
Morbus Bowen 
One pat ient  with M. Bowen on the back  of 
the left fifth f inger and adjacent  hand was 
accepted for ALA-PDT, a l though cl inical ly 
there was some doubt whether  certa in areas 
showed a beginning of inf i l trat ive growth. The 
maximal  response was seen after 2 months 
with >90% reduct ion in tumour  area, which 
was approx imate ly  5 cm 2 before PDT. Only a 
small crust of about  5 mm remained. Subse- 
quently, the tumour  started growing again, 
and barely responded to a second ALA-PDT 
treatment.  Subsequent reatment  with radio- 
therapy (54 Gy) produced a CR. 
Actinic keratosis 
Three patients,  two with extensively pre- 
t reated lesions, received ALA-PDT. One 
pat ient  had lesions of act inic keratosis  in an 
area adjacent  o del icate skin on the skull, 2 yr 
after rad iotherapy for an u lcerat ing BCC. The 
lesion showed a CR without  damage to the 
i r radiated skin. The second pat ient  had multi- 
ple lesions on the skull, t reated extensively 
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No. No. 
of of 
patients lesions 
Recurrence 
CR PR PD 
after CR 
BCNS 2 >250 a 
BCNS b 1 22 22 (100%) 
BCC 16 42 34 (81%) c 
Actinic keratosis 3 5 3 (60%) c 
Chronic 1 2 
Inflammation 
Morbus Bowen 1 1 
Metastasized BCC 1 8 
a a a 
8 (19%) 1 (3%) 
2 (40%) 1 (20%) 
2 (100%) 
1 (100%) 
8 (100%) 
ALA-PDT, 5-aminolaevulinic acid photodynamic therapy; CR, complete response; PR, partial 
response; PD, progressive disease; BCNS, basal cell naevus syndrome; BCC, basal cell 
carcinoma. 
CAll types of responses were seen; a few areas treated with green light (514.5 rim). 
bTreated only with green light (514.5 nm). 
CNot corrected for recurrence. 
with conservat ive methods (ointments), sur- 
gery and cryotherapy.  Two ulcers appeared to 
be due to chronic inf lammation.  All act inic 
keratot ic  lesions d isappeared after ALA-PDT. 
The chronic ulcers showed some regression 
which further  improved after conservat ive 
t reatment.  The third pat ient  had res istant  
actinic keratos is  just crania l  to his left eye- 
brow, responding near ly  completely to one 
ALA-PDT session. Eight months later, recur- 
rence was seen, which responded incompletely 
to a second ALA-PDT treatment.  The lesion 
was excised surgical ly.  Histology showed 
extensive act inic keratosis  but also foci of 
inf i l trat ing squamous cell carcinoma. 
Oral 5-aminolaevulinic acid 
One pat ient  presented for ALA-PDT after 
extensive surgery and rad iotherapy for meta- 
stasized BCC. After mult ip le recurrences in 
the frontal  skin, lymph node metastases had 
developed. Later,  in t racutaneous  metastases 
appeared in the face and in the neck. Surgery 
or rad iotherapy were no longer possible for 
this disfigured patient.  5-Aminolaevul inic acid 
was given oral ly in orange juice (50 mg kg-1  
body weight) after which PpIX f luorescence 
of the skin which was part icu lar ly  strong in 
the surgical ly-treated parts  of the face could 
be observed. Eight areas were i l luminated, 
started 4 h after ingest ion of ALA (16, 17) and 
completed 3 h later. The pat ient  felt pain in the 
areas on the face that  showed strong fluor- 
escence, and some itching elsewhere. The 
response to PDT was insignif icant, however,  
and later t reatment  with topical  ALA-PDT was 
ineffective. 
DISCUSSION 
Fluorescence excitation spectrum and 
ALA-PDT action spectrum 
On the basis of previous experience with 
Photofr in (14), the wavelength of the max imum 
in the in vivo PpIX f luorescence xcitat ion 
spectrum, 633 nm for PpIX, was chosen as the 
opt imum wavelength for ALA-PDT. Recently, 
Szeimies et al (18) studied the act ion spectrum 
for ALA-PDT both in vitro and in vivo. In 
vitro, the opt imum wavelength was found to be 
635 + 2 nm. In this regard, the possibi l i ty of a 
small blue-shift from in vitro to in vivo should 
be considered (13, 14). In vivo, only the differ- 
ence between 630 nm and 635 nm was detected, 
635 nm being more effective (18). Considering 
the exper imental  errors, the difference with 
the results of the present paper  is not sig- 
nificant. In cl inical practice, the difference 
between the ALA-PDT effect at 633 nm and at 
635 nm would probably  not be measureable.  
For tru ly superficial lesions, green l ight 
(514.5 nm) from the argon laser may be a good 
a l ternat ive for red light, if a laser is avai lable. 
Because of the h igh power avai lable, this could 
make it possible to t reat  large areas in a 
relat ively short  time. 
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Clinical  results  of ALA-PDT 
This study confirms that ALA-PDT can have a 
role in the curative and palliative treatment 
of superficial pre-malignant skin lesions, 
although it must compete with highly success- 
ful standard treatments. With cryotherapy or 
surgery, a 90-95% success rate is usually 
achieved for small lesions (19-23). Similar high 
cure rates can be achieved with fractionated 
radiotherapy. For good cosmetic results, this 
requires an overall treatment ime of 3M 
weeks (24). Radiotherapy is a highly successful 
therapy for larger superficial as well as deeply 
invasive lesions, for lesions in anatomical 
areas not easily accessible for surgery, and 
in patients with relative or absolute contra- 
indications to surgery. 
The present results are in the same range as 
reported by other authors, although the 
number of patients is relatively small. For 
treatment of BCCs, a CR rate of 81% was 
achieved 3 months after treatment. Kennedy 
et al (9) reported 90% CR for BCCs after 2--3 
months, and 79% in a more recent paper (12). 
Cairnduff (25) achieved a CR of 88%, which fell 
to 50% after 17 months follow-up. This result 
was influenced considerably by the negative 
selection of her patients. Most patients re- 
ferred for ALA-PDT were elderly people and 
had large lesions, considered less suitable for 
standard treatment. Several other studies have 
been published recently, reporting 80-100% 
CR for superficial BCCs (26 29). Nodular 
BCCs generally require multiple treatments o
achieve CR. 
One patient with M. Bowen was treated with 
PR as best result, although the response was 
quite significant (see Results). Clinically, there 
was some doubt whether certain areas showed 
early infiltrative growth, but this was not 
confirmed in biopsies. Possibly, ALA-PDT 
failed in the thickest areas. Cairnduff (25) 
and Calzavara-Pinton (26) reported excellent 
results for patients with M. Bowen (89% CR 
after 18 months, and 100% CR, respectively), 
showing that M. Bowen is a good indication 
for ALA-PDT. 
The patients with actinic keratosis all had 
a history of different herapies, not resulting 
in a CR. In one patient, ALA-PDT gave an 
excellent PR, resulting in only a tiny remain- 
ing spot of 2 mm diameter. Ten months later, 
however, a recurrence appeared which did not 
respond to a second ALA-PDT treatment. After 
surgical excision, a squamous cell carcinoma 
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appeared in one spot, indicating again that in 
the course of the disease, malignant degenera- 
tion can occur, a possibility which should 
always be borne in mind. 
The present results with three BCNS 
patients were satisfying. The 22 BCCs of one 
patient all responded completely. The second 
patient had multiple lesions all over his body. 
Treatment of the most active lesions resulted 
in a clinical PR, and the appearance of the 
treated lesions showed no sign of progression 
after 15 months of follow-up. The third patient 
had extensive disease with BCCs all over the 
head, trunk and arms, confluent in areas 
treated previously with :radiotherapy. For this 
patient, ALA-PDT has provided satisfactory 
palliation, with a CR of many superficial 
lesions. The main goal of treatment is pallia- 
tion, which can be achieved only with the help 
of cryotherapy and surgery for the larger 
lesions. In order to improve the response of 
non-superficial lesions, ALA was applied over- 
night (16-19 h). This appeared to improve ALA 
penetration and thus the depth of treatment. 
By repeated treatments using overnight ALA 
application, complete responses of some non- 
superficial BCCs could be achieved. Selective 
turnout fluorescence, observed after ~6 h ALA 
application (Fig. 2), was absent in this 
patient after 16-19 h application, because the 
ALA-exposed normal skin showed as much 
fluorescence as the tumour. Nevertheless, the 
cosmetic result following PDT was not affected 
adversely. 
Encouraged by these results, seven patients 
with BCCs were treated after 16h of ALA 
application (Table 2). This avoids waiting 
3 6h, since the ALA is applied in the late 
afternoon and the illumination is clone the 
next day. Although the selective turnout flu- 
orescence was lost, the cosmetic result did 
not deteriorate. No telangiectasia, fibrosis 
or contractions were seen. However, the 
authors had the strong impression that 
the patients felt more pain during treatment 
after 16h. This is likely to be the result 
of increased ALA penetration (30, 31). Also, 
fluorescence was observed in normal adja- 
cent skin after 12 h ALA application (30). 
Kennedy (4) did not observe ALA passage 
through normal keratin after 6 h. The differ- 
ence might be explained by a delayed penetra- 
tion of the lipophilic stratum corneum by 
hydrophilic ALA. This would also explain the 
relative tumour selectivity after 4h ALA 
application. 
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Fig. 2. (a) Photograph of two basal cell carcinoma (BCC) lesions on the chest wall of a basal celt naevus syndrome patient. 
(b) Fluorescence of the same lesion in (a) photographed through an RG665 coloured glass filter during illumination with green 
laser light (514.5 nm). The BCC lesions are demarcated clearly. The fluorescent dots are hair follicles. 5-aminolaevulinic acid 
(ALA) application time =4 h. When the ALA application time was 16-19 h, selective tumour fluorescence was lost in this 
patient: the whole area where ALA had been applied showed nearly the same fluorescence intensity. 
Table 2. Results with different ALA application times for 16 patients with BCC 
ALA application time 
No. of No. of Recurrence 
CR PR 
patients lesions after CR 
3-6 h 9 32 25 (78%) 6 (1.9%) t (3%) 
16-19 h 7 10 8 (80%) 2 (20%) 0 (0%) 
Second ALA application ~ 4 4 1 (25%) 3 (75%) 0 (0%) 
ALA, 5-aminolaevulinic a id; BCC, basal cell carcinoma; CR, complete response; PR, partial 
response. 
"Two ALA applications of 4h, two applications of 16h; the CR was observed after 16h 
application. 
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Pain 
According to several  recent authors (26, 28), 
only minor  discomfort occurs, but other 
authors  apply an anaesthet ic  rout inely (25, 32). 
In the present authors '  experience, some form 
of pain medicat ion is pract ical ly  a lways 
required. Oral  pain rel ievers such as paraceta-  
mol, naproxen and t ramadol  are often insuffi- 
cient. Topical  appl icat ion of Emla | cream and 
l idocaine inf i l trat ion were appl ied with vary- 
ing success. 5-Aminolaevul inic-acid-PDT was 
part icu lar ly  painful  for two pat ients with BCC 
on the nose, i l luminated after 16-19 h of ALA 
appl icat ion. Only Emla | was applied, which 
was not completely effective, and the pain 
in one case lasted for several  days after the 
treatment.  
Possible improvements 
Although the high init ial  CR rates of topical  
ALA-PDT have been reported before (28, 29), 
recurrences occur and the histological  
response rates are lower (25, 26, 33). Also, the 
CR rates of nodular  BCC are less favourable.  
Messmann et al (34) and Hua et al (35) showed 
exper imental ly  that  the effect of PDT after 
systemic ALA administ rat ion can be increased 
by l ight fract ionat ion.  Van der Veen et al (36) 
showed that  with one systemic ALA dose, 
the PDT effect could be increased when a 
second i l luminat ion was given, fol lowing 
re-appearance of PpIX f luorescence 1-2 h after 
the f luorescence had been photobleached by 
the first i l lumination. These effects may also 
occur after topical  ALA. Other possibi l it ies for 
improvement  are the use of DMSO, EDTA 
(27, 29) or desferr ioxamine (32). 
CONCLUSIONS 
Photodynamic  therapy using topical  ALA 
appl icat ion yields high CR rates in superficial 
BCC. Less favourable response rates have also 
been reported in the l i terature,  in part icu lar  
for nodular  lesions. The differences may be the 
result  of pat ient  select ion and durat ion of 
follow-up. Differences in t reatment  protocols 
may also play a role. Histological  CR rates are 
lower than clinical CR rates. All authors,  
except F i jan (32), reported the same high 
response rates for Bowen's disease. In 
addit ion, actinic keratosis,  cutaneous T-cell 
P.J.N. Meijnders, W.M. Star, R.S. de Bruijn et al 
l ymphoma (37, 38) and superficial squamous 
cell carc inoma (26) responds well to topical  
ALA-PDT. 
Due to the photobleaching of the PPIX, the 
t reatment  is self-limiting. This effect also 
reduces the r isk of overdosage in over lapping 
l ight fields when larger areas are treated. This 
self- l imiting property  of ALA-PDT also l imits 
the therapeut ic  effect. This may be overcome 
by a longer ALA appl icat ion combined with 
var ious forms of l ight f ract ionat ion (35, 36). 
Cosmetic results were good to excellent. 
In two patients,  keloid format ion in the 
scar occurred after plastic surgery. 5- 
Aminolaevul in ic-acid-PDT in these pat ients  
caused no scar tissue, and the or iginal  tumour  
site could only be located using the pre- 
t reatment  colour slides. In the authors '  experi- 
ence, pain dur ing and after PDT is often a 
problem. A non- invasive method to rel ieve 
pain, that  does not require inject ion of a drug 
in or under the lesion, would be desirable. 
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